Search for tag: "oncology"

23 Media

01:48 imCORE Scientific Collaborations imCORE Scientific Collaborations	imCORE Scientific Collaborations imCORE (immunotherapy Centers Of Research Excellence) is the leading academic-industry partnership in cancer immunotherapy (CIT). Led by Roche Genentech, it is a global network of leading scientific… imcore cit citc cancer immunotherapy oncology From Jane Piper on September 15th, 2021 0 likes 3 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No Language (In English) English
05:30 gRED Site Strategy (Canada)_SAT (Aug 2021) gRED Site Strategy (Canada)_SAT (Aug 2021)	gRED Site Strategy (Canada)_SAT (Aug 2021) A snapshot of the 3 sites that gRED is developing relationships with, as long-term development partners (Aug 2021) site relationships customer centricity clinical operations clinical science oncology roche canada From Mike Spoganetz on August 26th, 2021 0 likes 17 plays 0 Content Declaration Keep for 90 Days COREMAP Content classification C4 No Language (In English) English
09:52 Two Guys Call Into a Conference.. (AACI 2021… Two Guys Call Into a Conference.. (AACI 2021 Recap, A&P gRED [DO MS])	Two Guys Call Into a Conference.. (AACI 2021 Recap, A&P gRED [DO MS]) Dan Otap and Mike Spoganetz (Sr Alliance & Partnerships Leaders, A&P) talk us through some meaningful highlights of this year's American Association of Cancer Institutes (AACI) congress. aaci congresses oncology siteintelligence gred From Mike Spoganetz on August 3rd, 2021 4 likes 73 plays 1 Content Declaration Keep for 3 Years COREMAP Content classification C4 No
06:19 IPATential150: PI3K/AKT biomarkers VIDEO IPATential150: PI3K/AKT biomarkers VIDEO	IPATential150: PI3K/AKT biomarkers VIDEO PI3K/AKT pathway biomarkers analysis from the Phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer atezolizumab tecentriq asco gu oncology immunotherapy From Ankush Kalbalia on February 18th, 2021 0 likes 13 plays 0 Content Declaration Keep for 3 Years Language (In English) English
03:24 CONTACT-03 VIDEO CONTACT-03 VIDEO	CONTACT-03 VIDEO CONTACT-03 atezolizumab tecentriq oncology immunotherapy asco gu From Ankush Kalbalia on February 18th, 2021 0 likes 11 plays 0 Content Declaration Keep for 3 Years Language (In English) English
04:30 CONTACT-02 VIDEO CONTACT-02 VIDEO	CONTACT-02 VIDEO CONTACT-02 VIDEO atezolizumab tecentriq oncology asco gu immunotherapy From Ankush Kalbalia on February 18th, 2021 0 likes 6 plays 0 Content Declaration Keep for 3 Years Language (In English) English
04:48 CheckMate 9KD Arm B VIDEO CheckMate 9KD Arm B VIDEO	CheckMate 9KD Arm B VIDEO CheckMate 9KD arm B final analysis atezolizumab tecentriq asco gu oncology immunotherapy From Ankush Kalbalia on February 18th, 2021 0 likes 9 plays 0 Content Declaration Keep for 3 Years Language (In English) English
05:23 CAPItello-281 VIDEO CAPItello-281 VIDEO	CAPItello-281 VIDEO A phase 3 trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer atezolizumab oncology tecentriq asco gu immunotherapy From Ankush Kalbalia on February 18th, 2021 0 likes 3 plays 0 Content Declaration Keep for 3 Years Language (In English) English
02:47 HIF2a + cabozantinib phase II VIDEO HIF2a + cabozantinib phase II VIDEO	HIF2a + cabozantinib phase II VIDEO HIF2a + cabozantinib phase II VIDEO atezolizumab tecentriq immunotherapy asco gu oncology From Ankush Kalbalia on February 18th, 2021 0 likes 1 plays 0 Content Declaration Keep for 3 Years Language (In English) English
06:47 CheckMate 274 VIDEO CheckMate 274 VIDEO	CheckMate 274 VIDEO First result from the phase 3 Checkmate 274 trial of adjuvant nivolumab versus placebo in patients who underwent radical surgery for high risk muscle-invasive urothelial carcinoma atezolizumab tecentriq oncology asco gu immunotherapy From Ankush Kalbalia on February 18th, 2021 0 likes 17 plays 0 Content Declaration Keep for 3 Years Language (In English) English
02:17 Cell cycle progression and PTEN VIDEO Cell cycle progression and PTEN VIDEO	Cell cycle progression and PTEN VIDEO Cell cycle progression and PTEN VIDEO atezolizumab tecentriq oncology immunotherapy asco gu From Ankush Kalbalia on February 18th, 2021 0 likes 5 plays 0 Content Declaration Keep for 3 Years Language (In English) English
04:08 KEYNOTE-365 Cohort B VIDEO KEYNOTE-365 Cohort B VIDEO	KEYNOTE-365 Cohort B VIDEO KEYNOTE 365 cohort B asco gu immunotherapy tecentriq atezolizumab oncology From Ankush Kalbalia on February 17th, 2021 0 likes 11 plays 0 Content Declaration Keep for 3 Years Language (In English) English
03:35 Checkmate 9ER VIDEO Checkmate 9ER VIDEO	Checkmate 9ER VIDEO Checkmate 9ER VIDEO atezolizumab tecentriq oncology immunotherapy asco gu From Ankush Kalbalia on February 17th, 2021 0 likes 14 plays 0 Content Declaration Keep for 3 Years Language (In English) English
03:55 HIF2a + lenvatinib vs cabozantinib Phase III VIDEO HIF2a + lenvatinib vs cabozantinib Phase III VIDEO	HIF2a + lenvatinib vs cabozantinib Phase III VIDEO HIF2a + lenvatinib vs cabozantinib Phase III VIDEO asco gu tecentriq oncology atezolizumab immunotherapy From Ankush Kalbalia on February 17th, 2021 0 likes 12 plays 0 Content Declaration Keep for 3 Years
04:15 OS in PTEN LOF mCRPC OS in PTEN LOF mCRPC	OS in PTEN LOF mCRPC Overall Survival in patients with mCRPC who have PTEN tumor suppressor gene loss of function tecentriq atezolizumab oncology immunotherapy asco gu From Ankush Kalbalia on February 17th, 2021 0 likes 8 plays 0 Content Declaration Keep for 3 Years Language (In English) English
04:38 EV-301 VIDEO EV-301 VIDEO	EV-301 VIDEO Primary results of EV-301 atezolizumab tecentriq oncology asco gu immunotherapy From Ankush Kalbalia on February 17th, 2021 0 likes 8 plays 0 Content Declaration Keep for 3 Years Language (In English) English